MusclePharm Corp
company.status.inactiveCIK 1415684fmd_1DH3KQG57NVX7F1JVPTYDM25TEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2022, 49 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 67 | 111 | 177 | 167 | 132 | 94 | 88 | 80 | 64 | 50 |
| Cost of revenue | 53 | 78 | 121 | 110 | 88 | 71 | 70 | 71 | 45 | 45 |
| Gross profit | 14 | 33 | 56 | 57 | 44 | 23 | 18 | 9 | 20 | 5 |
| Research and development | 0 | 1 | 4 | 4 | 2 | 1 | 1 | 1 | – | – |
| Selling, general and administrative | 5 | 7 | 13 | 19 | 16 | 14 | 12 | 10 | 17 | 14 |
| Compensation and benefits | 5 | 12 | 25 | 31 | 18 | 10 | 8 | 8 | 6 | – |
| Total operating expenses | 23 | 47 | 75 | 107 | 53 | 30 | 26 | 24 | 17 | 14 |
| Operating income | (9) | (14) | (19) | (50) | (9) | (7) | (8) | (15) | 3 | (9) |
| Interest expense | – | – | – | – | – | 4 | 4 | 4 | 1 | 5 |
| Other non-operating income (expense) | (10) | (3) | 6 | (2) | (2) | (4) | – | – | 0 | 2 |
| Income before taxes | (19) | (18) | (14) | (52) | (3) | (12) | (11) | (19) | 3 | (13) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (0) | (0) |
| Net income from continuing operations | (19) | (18) | (14) | (52) | (3) | (13) | (11) | (19) | 3 | (13) |
| Net income | (19) | (18) | (14) | (52) | (3) | (13) | (11) | (19) | 3 | (13) |
| Net income to common shareholders | (19) | – | – | – | – | – | – | – | – | – |